Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | VNN1 | O95497 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436995 | 0.84 | P2RX7 (0.36) | P2RX7VNN1SCDSCD5NAMPT | |
| SCHEMBL19286500 | 0.81 | P2RX7 (0.34) | P2RX7VNN1SCDSCD5NAMPT | |
| SCHEMBL18843016 | 0.81 | P2RX7 (0.34) | P2RX7VNN1SCDSCD5NAMPT | |
| SCHEMBL15505981 | 0.79 | P2RX7 (0.33) | P2RX7SCDSCD5ADRA1A | |
| SCHEMBL20969052 | 0.78 | CHRM1 (0.33) | P2RX7ADRA1A | |
| SCHEMBL23073866 | 0.76 | P2RX7 (0.32) | P2RX7SCDSCD5 | |
| SCHEMBL19017302 | 0.75 | DPP4 (0.32) | — | |
| SCHEMBL20227949 | 0.75 | PDPK1 (0.40) | NAMPT | |
| SCHEMBL6369633 | 0.74 | SCD (0.36) | P2RX7VNN1SCDSCD5NAMPT | |
| SCHEMBL15697005 | 0.73 | P2RX7 (0.34) | P2RX7VNN1SCDSCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225493-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-01-18 | — | — | US | disclosed |
| EP-3571208-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2020-09-03 | — | — | US | disclosed |
| US-10759750-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190127323-A1 | Novel Beta Lactams as Modulators of Glutamate Uptake and Methods for Use Thereof | Temple University--of the Commonwealth System of Higher Education | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759750-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | SLC1A2, SLC1A1, SLC7A11 | P2RX7 1937/4885VNN1 650/4885SCD 567/4885 |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | P2RX7 3197/4885VNN1 2558/4885SCD 3811/4885 |
| US-11225493-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | P2RX7 3197/4885VNN1 2558/4885SCD 3811/4885 |
| US-20190127323-A1 | Novel Beta Lactams as Modulators of Glutamate Uptake and Methods for Use Thereof | SLC1A2, SLC1A1, SLC7A11 | P2RX7 2038/4885VNN1 630/4885SCD 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.